Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Vasculitis
•
Systemic lupus erythematosus
•
Cyclophosphamide
•
General Rheumatology
•
Infectious Disease
•
Tuberculosis
•
Latent Tuberculosis
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
Related Questions
How do you approach ongoing screening for TB in patients with a history of treated latent TB, but who have ongoing use of DMARDs and/or biologics given Quantiferon testing and PPD can remain positive?
How do you approach the management of digital ischemia in a critically ill patient with infection, but no evidence of active rheumatologic disease?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
How would you approach evaluation of a patient with multiple vertebral artery pseudoaneurysms and history of dissection, but without other areas of pseudoaneurysms?
How would you approach management of nodular scleritis in the setting of suspected GCA?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
What would be the preferred treatment option for PMR if patient develops gastric perforation soon after initiation of steroids?
